Voyager Therapeutics (NASDAQ:VYGR) Shares Gap Down to $13.85

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Rating) gapped down prior to trading on Tuesday . The stock had previously closed at $13.85, but opened at $13.48. Voyager Therapeutics shares last traded at $12.38, with a volume of 283,651 shares changing hands.

Analyst Upgrades and Downgrades

VYGR has been the topic of several recent research reports. TheStreet raised shares of Voyager Therapeutics from a “d” rating to a “c+” rating in a report on Friday, May 19th. Truist Financial initiated coverage on shares of Voyager Therapeutics in a report on Wednesday, May 10th. They issued a “buy” rating and a $18.00 price target on the stock. Oppenheimer assumed coverage on Voyager Therapeutics in a research report on Thursday, March 9th. They set an “outperform” rating and a $14.00 price target on the stock. Finally, StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, May 11th.

Voyager Therapeutics Stock Performance

The firm’s 50 day moving average is $8.66 and its 200-day moving average is $7.60. The stock has a market capitalization of $569.94 million, a price-to-earnings ratio of 5.74 and a beta of 1.12.

Voyager Therapeutics (NASDAQ:VYGR – Get Rating) last issued its quarterly earnings data on Tuesday, March 7th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.04). Voyager Therapeutics had a positive return on equity of 95.18% and a negative net margin of 24.21%. The firm had revenue of ($1.55) million during the quarter, compared to analyst estimates of $12.71 million. As a group, sell-side analysts forecast that Voyager Therapeutics, Inc. will post 1.01 earnings per share for the current year.

Insiders Place Their Bets

In other news, VP Robert W. Hesslein sold 4,410 shares of the business’s stock in a transaction that occurred on Monday, March 20th. The stock was sold at an average price of $7.76, for a total value of $34,221.60. Following the completion of the sale, the vice president now directly owns 102,200 shares in the company, valued at $793,072. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Voyager Therapeutics news, CEO Alfred Sandrock sold 7,437 shares of the stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $7.83, for a total transaction of $58,231.71. Following the transaction, the chief executive officer now directly owns 214,618 shares of the company’s stock, valued at $1,680,458.94. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Robert W. Hesslein sold 4,410 shares of Voyager Therapeutics stock in a transaction dated Monday, March 20th. The shares were sold at an average price of $7.76, for a total transaction of $34,221.60. Following the completion of the sale, the vice president now owns 102,200 shares in the company, valued at approximately $793,072. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,953 shares of company stock worth $147,684. 22.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of VYGR. Citigroup Inc. purchased a new stake in Voyager Therapeutics during the 1st quarter worth approximately $186,000. BlackRock Inc. increased its position in shares of Voyager Therapeutics by 10.6% during the first quarter. BlackRock Inc. now owns 514,155 shares of the company’s stock worth $3,919,000 after purchasing an additional 49,319 shares in the last quarter. Lazard Asset Management LLC raised its stake in Voyager Therapeutics by 144.7% in the 1st quarter. Lazard Asset Management LLC now owns 17,678 shares of the company’s stock valued at $134,000 after purchasing an additional 10,455 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new position in Voyager Therapeutics in the 1st quarter valued at $122,000. Finally, Northern Trust Corp boosted its stake in Voyager Therapeutics by 2.2% during the 1st quarter. Northern Trust Corp now owns 79,119 shares of the company’s stock worth $603,000 after purchasing an additional 1,683 shares during the last quarter. 59.58% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

(Get Rating)

Voyager Therapeutics, Inc is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A.